{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":24,"description":"Patients will receive 200 mg/m\\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).\n\nMelphalan HCl for injection (propylene glycol free): During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.","id":"EG000","otherNumAffected":24,"otherNumAtRisk":24,"seriousNumAffected":0,"seriousNumAtRisk":24,"title":"Melphalan HCl for Injection (Propylene Glycol Free)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Myeloablation as expected","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":24,"numEvents":24}],"term":"leukopenia"}],"timeFrame":"100 days post transplant"}